Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 60.83 |
| Open | 60.98 |
| 1-Year Change | 7.83% |
| Day's Range | 60.98 - 62.32 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 60.83 | 0.56 | 0.93% | 60.27 | 61.90 | 59.89 |
| Mar 31, 2025 | 60.27 | 0.56 | 0.94% | 59.71 | 60.73 | 59.03 |
| Mar 28, 2025 | 60.52 | 0.34 | 0.56% | 60.18 | 60.85 | 60.18 |
| Mar 27, 2025 | 60.55 | -0.67 | -1.09% | 61.22 | 61.40 | 60.07 |
| Mar 26, 2025 | 60.97 | -0.30 | -0.49% | 61.27 | 62.76 | 60.62 |
| Mar 25, 2025 | 61.72 | -0.94 | -1.50% | 62.66 | 63.07 | 60.93 |
| Mar 24, 2025 | 62.68 | 0.97 | 1.57% | 61.71 | 63.18 | 61.71 |
| Mar 21, 2025 | 61.78 | 1.88 | 3.14% | 59.90 | 62.26 | 59.90 |
| Mar 20, 2025 | 60.42 | 0.46 | 0.77% | 59.96 | 61.56 | 59.96 |
| Mar 19, 2025 | 60.27 | 0.37 | 0.62% | 59.90 | 61.07 | 59.66 |
| Mar 18, 2025 | 59.85 | -0.84 | -1.38% | 60.69 | 60.69 | 58.31 |
| Mar 17, 2025 | 61.91 | 2.55 | 4.30% | 59.36 | 63.38 | 58.62 |
| Mar 14, 2025 | 67.51 | 0.41 | 0.61% | 67.10 | 68.06 | 66.91 |
| Mar 13, 2025 | 67.37 | -0.31 | -0.46% | 67.68 | 68.88 | 67.21 |
| Mar 12, 2025 | 67.43 | 0.21 | 0.31% | 67.22 | 68.03 | 66.32 |
| Mar 11, 2025 | 67.79 | -2.63 | -3.73% | 70.42 | 71.20 | 67.17 |
| Mar 10, 2025 | 70.87 | 1.68 | 2.43% | 69.19 | 71.75 | 68.94 |
| Mar 7, 2025 | 70.66 | 1.25 | 1.80% | 69.41 | 72.67 | 69.00 |
| Mar 6, 2025 | 69.99 | 1.42 | 2.07% | 68.57 | 70.88 | 68.17 |
| Mar 5, 2025 | 69.54 | 0.57 | 0.83% | 68.97 | 69.80 | 68.59 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com